Literature DB >> 20148693

Methicillin-resistant Staphylococcus aureus colonization or infection in Canada: National Surveillance and Changing Epidemiology, 1995-2007.

Andrew E Simor1, Nicolas L Gilbert, Denise Gravel, Michael R Mulvey, Elizabeth Bryce, Mark Loeb, Anne Matlow, Allison McGeer, Lisa Louie, Jennifer Campbell.   

Abstract

OBJECTIVE: To determine the incidence and describe the changing epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection in Canadian hospitals from 1995-2007.
SETTING: Forty-eight hospitals participating in the Canadian Nosocomial Infection Surveillance Program.
DESIGN: Prospective, laboratory-based surveillance for incident cases of MRSA colonization or infection among hospitalized patients.
METHODS: Clinical and epidemiologic data were obtained by review of hospital records. Standard criteria were used to determine whether MRSA colonization or infection was present and whether the MRSA strain was healthcare associated or community associated. A representative subset of isolates was characterized by use of pulsed-field gel electrophoresis and staphylococcal cassette chromosome (SCC) mec typing.
RESULTS: From 1995 to 2007, a total of 37,169 hospitalized patients were newly identified as either infected or colonized with MRSA, and the overall incidence of both MRSA colonization and MRSA infection increased from 0.65 to 11.04 cases per 10,000 patient-days (P < .001). Of these 37,169 patients, 11,828 (32%) had an MRSA infection, and infection rate increased from 0.36 to 3.43 cases per 10,000 patient-days. The proportion of community-associated MRSA strains increased from 6% to 23% (P < .001). The most common genotype (47% of isolates) was CMRSA-2 (USA100/800); in 2007, CMRSA-10 (USA300) was the second most common strain (27% of isolates), associated with SCCmec type IV. Patients with CMRSA-10 were predominantly from western Canada and were more likely to be children (odds ratio [OR], 10.0 [95% confidence interval {CI}, 7.4-13.4]) and to have infection (OR, 2.3 [95% CI, 1.9-2.7]), especially skin and/or soft tissue infection (OR, 5.9 [95% CI, 5.0-6.9]).
CONCLUSIONS: The overall incidence of both MRSA colonization and MRSA infection increased 17-fold in Canadian hospitals from 1995 to 2007. There has also been a dramatic increase in cases of community-associated MRSA infection due to the CMRSA-10 (USA300) clone. Continued surveillance is needed to monitor the ongoing evolution of MRSA colonization or infection in Canada and globally.

Entities:  

Mesh:

Year:  2010        PMID: 20148693     DOI: 10.1086/651313

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  33 in total

1.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009.

Authors:  A R Caffrey; K L LaPlante
Journal:  Infection       Date:  2011-12-13       Impact factor: 3.553

2.  Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008.

Authors:  Andrew E Simor; Lisa Louie; Christine Watt; Denise Gravel; Michael R Mulvey; Jennifer Campbell; Allison McGeer; Elizabeth Bryce; Mark Loeb; Anne Matlow
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 3.  Virulence strategies of the dominant USA300 lineage of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  Lance R Thurlow; Gauri S Joshi; Anthony R Richardson
Journal:  FEMS Immunol Med Microbiol       Date:  2012-03-05

4.  National surveillance of methicillin-resistant Staphylococcus aureus in China highlights a still-evolving epidemiology with 15 novel emerging multilocus sequence types.

Authors:  Meng Xiao; He Wang; Ying Zhao; Lei-Li Mao; Mitchell Brown; Yun-Song Yu; Matthew V N O'Sullivan; Fanrong Kong; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

5.  Distribution of antiseptic resistance genes qacA, qacB, and smr in methicillin-resistant Staphylococcus aureus isolated in Toronto, Canada, from 2005 to 2009.

Authors:  Jean Longtin; Christine Seah; Krystal Siebert; Allison McGeer; Andrew Simor; Yves Longtin; Donald E Low; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use.

Authors:  Fawziah Marra; David M Patrick; Mei Chong; Rachel McKay; Linda Hoang; William R Bowie
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

7.  Immunization as a tool to combat antimicrobial resistance.

Authors:  J Spika; E W Rud
Journal:  Can Commun Dis Rep       Date:  2015-11-19

8.  Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study.

Authors:  Rachel D Savage; Robert A Fowler; Asgar H Rishu; Sean M Bagshaw; Deborah Cook; Peter Dodek; Richard Hall; Anand Kumar; François Lamontagne; François Lauzier; John Marshall; Claudio M Martin; Lauralyn McIntyre; John Muscedere; Steven Reynolds; Henry T Stelfox; Nick Daneman
Journal:  CMAJ Open       Date:  2016-10-13

9.  Emergence of new CMRSA7/USA400 methicillin-resistant Staphylococcus aureus spa types in Alberta, Canada, from 2005 to 2012.

Authors:  Vincent Li; Linda Chui; Kimberley Simmonds; Thuha Nguyen; George R Golding; Wadieh Yacoub; Christina Ferrato; Marie Louie
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

10.  Shedding of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus from adult and pediatric bathers in marine waters.

Authors:  Lisa R W Plano; Anna C Garza; Tomoyuki Shibata; Samir M Elmir; Jonathan Kish; Christopher D Sinigalliano; Maribeth L Gidley; Gary Miller; Kelly Withum; Lora E Fleming; Helena M Solo-Gabriele
Journal:  BMC Microbiol       Date:  2011-01-06       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.